Celgene (Nasdaq: CELG) has provided cause for celebration for Bristol-Myers Squibb (NYSE: BMY), which is set to take over the US biotech company, and its partner Acceleron Pharma (Nasdaq: XLRN).
The US Food and Drug Administration (FDA) has accepted reviews for the use of luspatercept in patients experiencing sickness who need red blood cell transfusions with both myelodysplastic syndromes and beta-thalassemia.
In the latter indication, the FDA has granted priority review to the application, and the agency has set a Prescription Drug User Fee Act (PDUFA) date of December 4. The PDUFA date for the MDS indication is April 4, 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze